Loss of Bacillus Calmette-Guerin Viability Adversely Affects the Direct Response of Urothelial Carcinoma Cells to Bacillus Calmette-Guerin Exposure

被引:6
作者
Shah, Gopitkumar
Zhang, Guangjian
Chen, Fanghong
Cao, Yanli
Kalyanaraman, Balaraman [2 ]
See, William [1 ]
机构
[1] Med Coll Wisconsin, Dept Urol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA
关键词
urinary bladder; carcinoma; BCG vaccine; cell survival; treatment outcome; BLADDER-CANCER; HMGB1; RELEASE; IMMUNOTHERAPY; GUIDELINES; THERAPY; GROWTH;
D O I
10.1016/j.juro.2013.09.012
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The attenuated mycobacterium bacillus Calmette-Guerin is widely used as intravesical immunotherapy for nonmuscle invasive urothelial carcinoma. Previous studies demonstrated that in the laboratory and clinical settings bacillus Calmette-Guerin viability is a variable that correlates with antitumor efficacy. We evaluated how loss of viability impacted a number of molecular and phenotypic intermediate end points that characterize and/or contribute to the direct effect of bacillus Calmette-Guerin on urothelial carcinoma cells. Materials and Methods: We studied the effect of loss of bacillus Calmette-Guerin viability on the tumor cell response to the treatment in 2 human urothelial carcinoma cell lines. The cellular response to bacillus Calmette-Guerin rendered nonviable by heat killing was compared to the response to viable bacillus. Response end points included the induction of oxidative stress, activation of intracellular signaling pathways, gene transactivation and phenotypic changes. Results: Loss of viability resulted in a quantitative decrease in the tumor cell response relative to that of viable bacillus Calmette-Guerin for all measured end points. The decrease in response varied by cell line, ranging from 15% to 100% of the response to viable bacillus. While responses were quantitatively different, nonviable bacillus continued to induce responses that were qualitatively similar to those of bacillus Calmette-Guerin relative to that in untreated controls. Conclusions: Bacillus Calmette-Guerin viability is an important variable influencing the direct tumor cell response to the treatment. Although the magnitude of its effects are attenuated, heat killed bacillus Calmette-Guerin remains active for the induction of bacillus Calmette-Guerin responsive biological end points.
引用
收藏
页码:823 / 829
页数:7
相关论文
共 23 条
  • [1] [Anonymous], GUIDELINE MANAGEMENT
  • [2] Bladder Cancer Immunotherapy: BCG and Beyond
    Askeland, Eric J.
    Newton, Mark R.
    O'Donnell, Michael A.
    Luo, Yi
    [J]. ADVANCES IN UROLOGY, 2012, 2012
  • [3] EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
    Babjuk, Marko
    Oosterlinck, Willem
    Sylvester, Richard
    Kaasinen, Eero
    Boehle, Andreas
    Palou-Redorta, Juan
    Roupret, Morgan
    [J]. EUROPEAN UROLOGY, 2011, 59 (06) : 997 - 1008
  • [4] MB49 Murine Urothelial Carcinoma: Molecular and Phenotypic Comparison to Human Cell Lines as a Model of the Direct Tumor Response to Bacillus Calmette-Guerin
    Chen, Fanghong
    Zhang, Guangjian
    Cao, Yanli
    Hessner, Martin J.
    See, William A.
    [J]. JOURNAL OF UROLOGY, 2009, 182 (06) : 2932 - 2937
  • [5] Generation of multinucleated giant cells in vitro by culture of human monocytes with Mycobacterium bovis BCG in combination with cytokine-containing supernatants
    Gasser, A
    Möst, J
    [J]. INFECTION AND IMMUNITY, 1999, 67 (01) : 395 - 402
  • [6] Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49)
    Günther, JH
    Frambach, M
    Deinert, I
    Brandau, S
    Jocham, D
    Böhle, A
    [J]. JOURNAL OF UROLOGY, 1999, 161 (05) : 1702 - 1706
  • [7] JACKSON AM, 1994, INT J ONCOL, V5, P697
  • [8] Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy
    Kassouf, Wassim
    Kamat, Ashish M.
    Zlotta, Alexander
    Bochner, Bernard H.
    Moore, Ronald
    So, Alan
    Izawa, Jonathan
    Rendon, Ricardo A.
    Lacombe, Louis
    Aprikian, Armen G.
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2010, 4 (03): : 168 - 173
  • [9] INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR SUPERFICIAL BLADDER-CANCER - EFFECT OF BACILLUS CALMETTE-GUERIN VIABILITY ON TREATMENT RESULTS
    KELLEY, DR
    RATLIFF, TL
    CATALONA, WJ
    SHAPIRO, A
    LAGE, JM
    BAUER, WC
    HAAFF, EO
    DRESNER, SM
    [J]. JOURNAL OF UROLOGY, 1985, 134 (01) : 48 - 53
  • [10] INHIBITION OF MURINE SARCOMA CELL ADHERENCE TO POLYSTYRENE SUBSTRATA BY BACILLUS-CALMETTE-GUERIN - EVIDENCE FOR FIBRONECTIN-MEDIATED DIRECT ANTITUMOR-ACTIVITY OF BCG
    KLEGERMAN, ME
    ZEUNERT, PL
    LOU, Y
    DEVADOSS, PO
    GROVES, MJ
    [J]. CANCER INVESTIGATION, 1993, 11 (06) : 660 - 666